Theodora Tsiouda
Aristotle University of Thessaloniki
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Theodora Tsiouda.
Journal of Thoracic Disease | 2014
Antonis Papaiwannou; Paul Zarogoulidis; Konstantinos Porpodis; Dionysios Spyratos; Ioannis Kioumis; Georgia Pitsiou; Athanasia Pataka; Kosmas Tsakiridis; Stamatis Arikas; Andreas Mpakas; Theodora Tsiouda; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Nikolaos Machairiotis; Stavros Siminelakis; Alexander Kolettas; George Kessis; Thomas Beleveslis; Konstantinos Zarogoulidis
Asthma and chronic obstructive pulmonary disease (COPD) are chronic diseases, very common in general population. These obstructive airway illnesses are manifested with chronic inflammation affecting the whole respiratory tract. Obstruction is usually intermittent and reversible in asthma, but is progressive and irreversible in COPD. Asthma and COPD may overlap and converge, especially in older people [overlap syndrome-asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS)]. Although ACOS accounts approximately 15-25% of the obstructive airway diseases, is not well recognised because of the structure of clinical trials. COPD studies exclude asthma patients and asthma studies exclude COPD patients, respectively. It is crucial to define asthma, COPD and overlap syndrome (ACOS), as notable clinical entities, which they share common pathologic and functional features, but they are characterized from differences in lung function, acute exacerbations, quality of life, hospital impact and mortality.
Journal of Thoracic Disease | 2014
Mihalis Argiriou; Styliani-Maria Kolokotron; Timothy Sakellaridis; Orestis Argiriou; Christos Charitos; Paul Zarogoulidis; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Nikolaos Machairiotis; Theodora Tsiouda; Kosmas Tsakiridis; Konstantinos Zarogoulidis
Right heart failure (RHF) is a frequent complication following left ventricular assist device (LVAD) implantation. The incidence of RHF complicates 20-50% (range, 9-44%) of cases and is a major factor of postoperative morbidity and mortality. Unfortunately, despite the fact that many risk factors contributing to the development of RHF after LVAD implantation have been identified, it seems to be extremely difficult to avoid them. Prevention of RHF consists of the management of the preload and the afterload of the right ventricle with optimum inotropic support. The administration of vasodilators designed to reduce pulmonary vascular resistance is standard practice in most centers. The surgical attempt of implantation of a right ventricular assist device does not always resolve the problem and is not available in all cardiac surgery centers.
Cancer Investigation | 2014
Paul Zarogoulidis; Fotini Katsikogianni; Theodora Tsiouda; Antonios Sakkas; Nikolaos Katsikogiannis; Konstantinos Zarogoulidis
Pro-inflammatory cytokines have been associated with chronic inflammation and inflammatory diseases. Increased levels of interleukins (ILs) have been associated with inflammatory disease exacerbation. ILs levels have been observed to be associated with advance stage cancer for several types of cancer and a poor prognostic maker for malignant disease. Moreover; increased levels of cytokines induce tumorigenesis. There are several paradigms such as the hepatocellular carcinoma induced from chronic inflammation of an underlying hepatitis. In the current review, we will focus on IL-8 and -17. These two ILs as in the case of others, induce neo-angiogenesis through activation of the vascular endothelial growth (VEGF) factor pathway. Additionally, they enhance the activity of matrix metalloproteinase-2 and –9 (MMP-2,-9) which in turn increase the metastatic activity of the underlying malignancy. Inhibition of cytokine production could be a potential treatment both for chronic inflammatory diseases and tumor modulation. Local microenvironment modulation could be applied in surgery resected patients as in the case of lung cancer in order to enhance the local immune activity.
Diagnostic Pathology | 2013
Nikolaos Machairiotis; Aikaterini Stylianaki; Georgios Dryllis; Paul Zarogoulidis; Paraskevi Kouroutou; Nikolaos Tsiamis; Nikolaos Katsikogiannis; Eirini Sarika; Nikolaos Courcoutsakis; Theodora Tsiouda; Andreas Gschwendtner; Konstantinos Zarogoulidis; Leonidas Sakkas; Aggeliki Baliaka; Christodoulos Machairiotis
Endometriosis is a clinical entity characterized by the presence of normal endometrial mucosa abnormally implanted in locations other than the uterine cavity. Endometriosis can be either endopelvic or extrapelvicdepending on the location of endometrial tissue implantation. Despite the rarity of extrapelvic endometriosis, several cases of endometriosis of the gastrointestinal tract, the urinarytract, the upper and lower respiratory system, the diaphragm, the pleura and the pericardium, as well as abdominal scars loci have been reported in the literature. There are several theories about the pathogenesis and the pathophysiology of endometriosis. Depending on the place of endometrial tissue implantation, endometriosis can be expressed with a wide variety of symptoms. The diagnosis of this entity is neither easy nor routine. Many diagnostic methods clinical and laboratory have been used, but none of them is the golden standard. The multipotent localization of endometriosis in combination with the wide range of its clinical expression should raise the clinical suspicion in every woman with periodic symptoms of extrapelvic organs. Finally, the therapeutic approach of this clinical entity is also correlated with the bulk of endometriosis and the locum that it is found. It varies from simple observation, to surgical treatment and treatment with medication as well as a combination of those.Virtual slidesThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1968087883113362.
Journal of Thoracic Disease | 2014
Athanasios Madesis; Kosmas Tsakiridis; Paul Zarogoulidis; Nikolaos Katsikogiannis; Nikolaos Machairiotis; Ioanna Kougioumtzi; George Kesisis; Theodora Tsiouda; Thomas Beleveslis; Alexander Koletas; Konstantinos Zarogoulidis
Mitral valve (MV) dysfunction is the second-most common clinically significant form of valvular defect in adults. MV regurgitation occurs with the increasing frequency of degenerative changes of the aging process. Moreover, other causes of clinically significant MV regurgitation include cardiac ischemia, infective endocarditis and rhematic disease more frequently in less developed countries. Recent evidence suggests that the best outcomes after repair of severe degenerative mitral regurgitation (MR) are achieved in asymptomatic or minimally symptomatic patients, who are selected for surgery soon after diagnosis on the basis of echocardiography. This review will focus on the surgical management of mitral insufficiency according to its aetiology today and will give insight to some of the perspectives that lay in the future.
Journal of Thoracic Disease | 2014
Konstantinos Porpodis; Paul Zarogoulidis; Dionysios Spyratos; Kalliopi Domvri; Ioannis Kioumis; Nikolaos Angelis; Maria Konoglou; Alexandros Kolettas; Georgios Kessisis; Thomas Beleveslis; Kosmas Tsakiridis; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Theodora Tsiouda; Michael Argyriou; Maria Kotsakou; Konstantinos Zarogoulidis
This review is focused on the relationship between asthma, pneumothorax and pneumomediastinum while presenting a number of case reports that include these conditions. The association between pneumothorax and asthma is not widely known. While asthma includes a common disorder and is prevalent worldwide, its morbidity and mortality is high when is associated with pneumothorax. Furthermore, the delayed diagnosis of pneumothorax while focusing on asthma includes the higher risk of coincidental pneumothorax in asthmatic patients. In addition, pneumomediastinum is considered benign and self-limiting condition that responds to conservative therapy. Although it is rare, the concurrence of pneumomediastinum with pneumothorax may prove fatal during a serious asthma attack. In conclusion, the symptoms of chest pain, dyspnea or focal chest findings when presented in asthmatic patients, must always create suspicion of pneumothorax or pneumomediastinum to the physician.
Journal of Thoracic Disease | 2014
Michael Koutentakis; Stavros Siminelakis; Panagiotis Korantzopoulos; Alexandra Petrou; Eleftheria Priavali; Andreas Mpakas; Eleftheria Gesouli; Eleftheria Apostolakis; Kosmas Tsakiridis; Paul Zarogoulidis; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Nikolaos Machairiotis; Theodora Tsiouda; Konstantinos Zarogoulidis
PURPOSE The infection of cardiac implantable electronic devices (CIED) is a serious and potentially lethal complication. The population at risk is growing, as the device implantation is increasing especially in older patients with associated comorbid conditions. Our purpose was to present the management of this complicated surgical condition and to extract the relevant conclusions. METHODS During a 3-year period 1,508 CIED were implanted in our hospital. We treated six cases of permanent pacemaker infection with localized pocket infection or endocarditis. In accordance to the recent AHA/ACC guidelines, complete device removal was decided in all cases. The devices were removed under general anaesthesia, with a midline sternotomy, under extracorporeal circulation on the beating heart. Epicardial permanent pacing electrodes were placed on the right atrium and ventricle before the end of the procedure. RESULTS The postoperative course of all patients was uncomplicated and after a follow up period of five years no relapse of infection occurred. CONCLUSIONS Management protocols that include complete device removal are the only effective measure for the eradication of CIED infections. Although newer technologies have emerged and specialized techniques of percutaneous device removal have been developed, the surgical alternative to these methods can be a safe solution in cases of infected devices.
Journal of Cancer | 2013
Kalliopi Domvri; Paul Zarogoulidis; Kaid Darwiche; Robert Browning; Qiang Li; J. Francis Turner; Ioannis Kioumis; Dionysios Spyratos; Konstantinos Porpodis; Antonis Papaiwannou; Theodora Tsiouda; Lutz Freitag; Konstantinos Zarogoulidis
Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet chemotherapy to the molecular targeted. The major limitation of the targeted therapies still remains the small number of patients positive to gene mutations. Furthermore, the differentiation between second line and maintenance therapy has not been fully clarified and differs in the clinical practice between cancer centers. The authors present a segregation between maintenance treatment and second line and present a possible definition for the term “maintenance” treatment. In addition, cancer cell evolution induces mutations and therefore either targeted therapies or non-specific chemotherapy drugs in many patients become ineffective. In the present work pathways such as epidermal growth factor, anaplastic lymphoma kinase, met proto-oncogene and PI3K are extensively presented and correlated with current chemotherapy treatment. Future, perspectives for targeted treatment are presented based on the current publications and ongoing clinical trials.
Journal of Thoracic Disease | 2014
Dionysios Spyratos; Paul Zarogoulidis; Konstantinos Porpodis; Nikolaos Angelis; Antonios Papaiwannou; Ioannis Kioumis; Georgia Pitsiou; Athanasia Pataka; Kosmas Tsakiridis; Andreas Mpakas; Stamatis Arikas; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Theodora Tsiouda; Nikolaos Machairiotis; Stavros Siminelakis; Michael Argyriou; Maria Kotsakou; George Kessis; Alexander Kolettas; Thomas Beleveslis; Konstantinos Zarogoulidis
During the last decades lung cancer is the leading cause of death worldwide for both sexes. Even though cigarette smoking has been proved to be the main causative factor, many other agents (e.g., occupational exposure to asbestos or heavy metals, indoor exposure to radon gas radiation, particulate air pollution) have been associated with its development. Recently screening programs proved to reduce mortality among heavy-smokers although establishment of such strategies in everyday clinical practice is much more difficult and unknown if it is cost effective compared to other neoplasms (e.g., breast or prostate cancer). Adding severe comorbidities (coronary heart disease, COPD) to the above reasons as cigarette smoking is a common causative factor, we could explain the low surgical resection rates (approximately 20-30%) for lung cancer patients. Three clinical guidelines reports of different associations have been published (American College of Chest Physisians, British Thoracic Society and European Respiratory Society/European Society of Thoracic Surgery) providing detailed algorithms for preoperative assessment. In the current mini review, we will comment on the preoperative evaluation of lung cancer patients.
Journal of Thoracic Disease | 2014
Nikolaos Angelis; Konstantinos Porpodis; Paul Zarogoulidis; Dionysios Spyratos; Ioannis Kioumis; Antonis Papaiwannou; Georgia Pitsiou; Kosmas Tsakiridis; Andreas Mpakas; Stamatis Arikas; Theodora Tsiouda; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Nikolaos Machairiotis; Michael Argyriou; George Kessisis; Konstantinos Zarogoulidis
Chronic obstructive pulmonary disease (COPD) is an inflammatory airway disease whose incidence and mortality increases every year. It is associated with an abnormal inflammatory response of the lung to toxic particles or gases (usually cigarette smoke). A central role in the pathophysiology has been shown to play a chronic inflammation of the airways that is expressed primarily by hypersecretion of mucus, stenosis of the smaller airways and the establishment of pulmonary emphysema. There is an increasing trend for assessing the inflammatory pattern of inflammatory airway diseases through mediators measured by noninvasive techniques. Markers in biological fluids and exhaled air have been the subject of intense evaluation over the past few years, with some of them reaching their introduction into clinical practice, while others remain as research tools. Of particular interest for the scientific community is the discovery of clinically exploitable biomarkers associated with specific phenotypes of the disease. Studying the effects of therapeutic interventions in these biomarkers may lead to targeted therapy based on phenotype and this is perhaps the future of therapeutics in COPD.